In 2025, Big Pharma plans to pursue acquisitions to replace lost revenue from expiring patents on major drugs, focusing on obesity and oncology markets.
Hutchmed, controlled by billionaire Li Ka-shing, is set to sell a $608 million stake in its health unit to enhance capital and focus on core operations.
Trump's proposed tariffs may raise drug prices and cause shortages, impacting the U.S. pharmaceutical market by increasing the cost and availability of medications.